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The mammalian APOBEC3 proteins are cytidine deaminases that function as inhibitors of retrovirus replication and retrotransposon mobility.
An issue that has remained controversial is whether the editing of deoxycytidine residues to deoxyuridine is necessary and sufficient for this
inhibition or whether APOBEC3 proteins also exert a second, distinct inhibitory mechanism. Here, we present an analysis of the ability of mutants
of APOBEC3G and APOBEC3B, both of which contain two consensus cytidine deaminase active sites, to inhibit the replication of human
immunodeficiency virus. Our data confirm that APOBEC3G only contains a single, carboxy-terminal active site but, surprisingly, reveal that both
cytidine deaminase consensus sequences in APOBEC3B are enzymatically active. Enzymatically inactive mutant forms of APOBEC3G and
APOBEC3B were found to retain the ability to inhibit the infectivity of HIV-1 virions produced in their presence by ∼4-fold and ∼8-fold,
respectively. While this inhibition was significantly less than the level seen with wild-type forms of A3G or A3B, these data, nevertheless argue
that the inhibition of HIV-1 by APOBEC3 proteins is at least partly independent of DNA editing.
© 2007 Elsevier Inc. All rights reserved.Keywords: APOBEC3G; DNA editing; Intrinsic immunity; HIV-1Introduction
The mammalian APOBEC3 protein family has emerged as a
key mediator of intrinsic immunity to retroviruses and retro-
transposons (reviewed by Cullen, 2006). This activity was first
observed in the case of human APOBEC3G (A3G), which was
identified as the key cellular factor blocking the replication of
human immunodeficiency virus type 1 (HIV-1) variants lacking
a functional vif gene (HIV-1ΔVif) (Sheehy et al., 2002). In
contrast, in cells infected with wild-type HIV-1, the viral Vif
protein directly binds to A3G and induces its degradation via the
proteasome (Conticello et al., 2003; Marin et al., 2003; Sheehy
et al., 2003; Stopak et al., 2003; Yu et al., 2003; Mehle et al.,
2004). Two other human APOBEC3 proteins, A3F and A3B,
are also potent inhibitors of HIV-1ΔVif. Like A3G, A3F is
expressed ubiquitously, including in the CD4+ T cells and mac-⁎ Corresponding author. Fax: +1 919 681 8979.
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doi:10.1016/j.virol.2007.03.019rophages normally infected by HIV-1, and A3F is also subject to
degradation by Vif (Bishop et al., 2004; Liddament et al., 2004;
Wiegand et al., 2004; Zheng et al., 2004; Liu et al., 2005). In
contrast, A3B is not detectably expressed in CD4+ T cells and
macrophages and, presumably as a result, the HIV-1 Vif protein
has not evolved the ability to neutralize A3B function (Bishop
et al., 2004; Yu et al., 2004a; Doehle et al., 2005).
In addition to A3G, A3F and A3B the human APOBEC3
family also includes A3A, A3C, A3DE and A3H (Jarmuz et al.,
2002; Dang et al., 2006; OhAinle et al., 2006). These latter four
proteins are unable to inhibit HIV-1ΔVif replication effectively,
although hA3DE does show weak inhibitory activity (Dang
et al., 2006). However, A3A has been shown to be a potent
inhibitor of a wide range of retrotransposons (Bogerd et al.,
2006a, 2006b; Chen et al., 2006; Muckenfuss et al., 2006) while
A3C has been reported to inhibit simian immunodeficiency
virus infectivity (Yu et al., 2004a).
All members of the APOBEC3 protein family, both human
and otherwise, contain either two copies (A3G, A3F, A3B and
A3DE) or a single copy (A3A, A3C, A3H) of the cytidine
deaminase consensus active site (CDA) HXEX23–28PCX2–4C
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The cysteine and histidine residues are believed to coordinate a
critical active site zinc ion while the glutamic acid residue
participates directly in the deamination reaction (Betts et al.,
1994). Importantly, all humanAPOBEC3 proteins analyzed thus
far, with the possible exception of A3DE, are indeed capable of
deaminating deoxycytidine to deoxyuridine and preferentially
deaminate deoxycytidine residues present on single-stranded
DNA (Suspène et al., 2004; Yu et al., 2004b). Initial research
suggested that this deamination activity was critical for
APOBEC3-mediated inhibition of HIV-1 replication as A3G,
A3F and A3B all induced extensive mutagenesis of the few
HIV-1ΔVif proviruses that were able to successfully integrate
into the genome of target cells after exposure to these proteins
(Harris et al., 2003; Mangeat et al., 2003; Zhang et al., 2003;
Bishop et al., 2004; Liddament et al., 2004;Wiegand et al., 2004;
Yu et al., 2004a; Zheng et al., 2004; Doehle et al., 2005). It
therefore appeared that A3G, A3F and A3B were being
selectively incorporated into retroviral virions (Alce and
Popik, 2004; Cen et al., 2004; Schäfer et al., 2004; Wiegand et
al., 2004; Zennou et al., 2004; Doehle et al., 2005; Khan et al.,
2005) and then, during a subsequent infection, were inducing
massive mutagenesis of the provirus by dC to dU editing of the
nascent DNAminus strand during reverse transcription. This led
either to the production of a lethally mutated provirus or, more
commonly, to the premature termination of reverse transcription
and/or the degradation of reverse transcription intermediates.
More recent research has challenged this model based on the
finding that someA3G andA3Fmutants that appear incapable of
catalyzing deamination of deoxycytidine nevertheless retain
substantial inhibitory activity against HIV-1 (Newman et al.,
2005; Bishop et al., 2006; Jónsson et al., 2006; Holmes et al.,
2007). In addition, A3A and A3B mutants that lack the ability to
induce cytidine deamination have been shown to effectively
inhibit themobility of the retrotransposons (Bogerd et al., 2006a,
2006b; Stenglein and Harris, 2006).
In this manuscript, we have sought to shed further light on the
role of cytidine deamination in the inhibition of retrovirus
function by human APOBEC3 proteins. We have analyzed the
effect of mutational inactivation of either one or both of the
CDAs present in A3G or A3B on their ability to inhibit the
replication of HIV-1. Our data argue that these CDAs play an
important but partially redundant role in mediating the observed
inhibition of retroviral replication and reveal that A3B, unlike
A3G and A3F, contains two enzymatically active CDAs that
both contribute to the mutational editing of HIV-1 proviruses
produced in the presence of A3B.
Results
Effect of A3G and A3B mutants on retroviral infectivity
As noted above, A3G and A3B contain two copies of the
CDA sequence HXEX23–28PCX2–4C, although it has been
reported for both A3G and A3B that only the carboxy-terminal
CDA is enzymatically active (Haché et al., 2005; Navarro et al.,
2005; Newman et al., 2005; Hakata and Landau, 2006; Jónssonet al., 2006; Stenglein and Harris, 2006). To examine the
contribution of the CDAs to the ability of A3G and A3B to
inhibit HIV-1 infectivity, we generated six mutants of A3G and
A3B that are predicted to disrupt either one or both CDA
sequences. In the case of A3G, we mutated the amino-terminal
active site glutamic acid (residue 67) to glutamine (A3G-E1)
or the carboxy-terminal site glutamic acid (residue 259) to glu-
tamine (A3G-E2), or changed both to glutamine (A3G-E1+2).
Alternatively, we mutated the first cysteine residue of the amino-
terminal CDA (residue 97) to serine (A3G-C1), the first cysteine
residue of the carboxy-terminal CDA (residue 288) to serine
(A3G-C2), or again changed both at once (A3G-C1+2). Based
on published work, these mutations, which either mutate the key
active site glutamic acid or prevent zinc binding, should disrupt
the activity of either one or both CDAs present in A3G (Newman
et al., 2005; Jónsson et al., 2006).
Very similar mutants were also constructed in the context of a
human A3B cDNA. These mutations changed glutamic acid 68
to glutamine (A3B-E1), glutamic acid 255 to glutamine (A3B-
E2), or both (A3B-E1+2). Alternatively, these mutations
introduced a serine in place of cysteine 97 (A3B-C1) or cysteine
284 (A3B-C2) or both (A3B-C1+2).
We next analyzed the ability of these mutant forms of A3G or
A3B to inhibit the infectivity of HIV-1 (Fig. 1) using a pre-
viously described experimental protocol (Wiegand et al., 2004;
Doehle et al., 2005). As shown in Fig. 1A, under the conditions
used, wild-type A3G inhibited the infectivity of HIV-1 by ∼30-
fold. Mutation of the amino-terminal CDA of A3G, in either
A3G-E1 or A3G-C1, led to an ∼3-fold inhibition in HIV-1
infectivity, i.e., 8- to 12-fold less than seen with wild-type A3G.
Similarly, A3G mutants bearing a defective carboxy-terminal
CDA, i.e., A3G-E2 and A3G-C2, inhibited HIV-1 infectivity by
only ∼4-fold, i.e., ∼8-fold less effectively than wild-type A3G.
Finally, when both CDAs in A3G were mutated in A3G-E1+2,
inhibition of HIV-1 infectivity was largely lost. Although the
A3G-C1+2 mutant did appear to reduce HIV-1 infectivity by up
to 4-fold in the experiments reported in Fig. 1A, this mutant
displayed ≤2-fold inhibitory activity in other experiments (data
not shown) and is therefore likely to share the minimal inhibitory
activity noted with the equivalent A3G-E1+2 mutant.
Analysis of the inhibition of HIV-1 by A3B mutants revealed
a slightly different picture (Fig. 1B). Like A3G, wild-type A3B
inhibited HIV-1 infectivity by ∼40-fold. This high level of
inhibition, which we have noted previously (Doehle et al., 2005;
Bogerd et al., 2006a), contrasts with the relatively modest
inhibition of HIV-1 infectivity by A3B noted by others (Yu
et al., 2004a; Bishop et al., 2006; Hakata and Landau, 2006;
Stenglein and Harris, 2006). While the reason(s) for this
consistent difference is not clear, we have noted that plasmids
containing the A3B gene occasionally undergo spontaneous C
to T editing in bacteria (data not shown), which could result in
reduced biological activity if not detected.
Mutation of the amino-terminal CDA of A3B, in A3B-E1 or
A3B-C1, had a fairly modest phenotypic effect, with the
observed inhibition of the infectivity of HIV-1 virions being
reduced to 10- to 15-fold, i.e., only 2- to 3-fold less than seen
with wild-type A3B. Mutation of the carboxy-terminal CDA of
Fig. 1. Effect of A3G and A3B mutants on HIV-1 infectivity and virion incorporation. (A) Inhibition of HIV-1 infectivity by wild-type and mutant A3G variants was
measured by co-transfecting 293T cells with the HIV-1 indicator vector pNL-LucΔVif and an APOBEC3 expression plasmid. At 48 h post-transfection, supernatant
virions were collected and used to infect naive 293Tcells. At 24 h later, these infected cells were lysed and induced luciferase levels determined. The data are presented
relative to virus derived from control cultures transfected with the parental pK vector in place of an APOBEC3 expression vector (NEG), which was set at 100%
infectivity. These data derive from three independent experiments with standard deviations shown. (B) Similar to panel A, except that 293T cells were co-transfected
with plasmids expressing wild-type or mutant A3B proteins. (C) 293T cells were co-transfected with the HIV-1 proviral plasmid pNL4-3ΔEnvΔVif and a plasmid
expressing carboxy-terminally HA-tagged A3G or an HA-tagged cytoplasmic control protein, β-arrestin (CONT). At 48 h post-transfection, the supernatant media
were harvested and filtered and virions collected by pelleting through a 20% sucrose cushion. At the time the supernatant media were harvested, we also collected the
virion producing 293Tcells. We then performedWestern analyses of the producer cell lysates and the lysed, pelleted virions using antibodies specific for the HA-tag or
specific for the HIV-1 capsid protein. (D) Similar to panel C, except that the intracellular expression and virion incorporation of A3B mutants was analyzed.
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phenotype, with the observed inhibition of HIV-1 infectivity
being reduced to 4- to 8-fold. The simultaneous mutation of both
CDAs also reduced the inhibition of HIV-1 infectivity by A3B
by ∼5-fold, leaving a significant residual inhibition of ∼8-fold
when compared to the level of HIV-1 infectivity seen in the
absence of any APOBEC3B protein (Fig. 1B).
Effect of CDA mutations on virion incorporation of A3G
and A3B
It has previously been reported that the amino-terminal CDA,
and particularly the zinc-coordinating residues of this CDA, play
an important role in mediating the specific incorporation of A3G
into HIV-1 virion particles (Navarro et al., 2005). To address
whether the various mutations introduced into A3G or A3B
affected their incorporation into HIV-1 virions, we isolated
virions produced from cells expressing these proteins by
ultracentrifugation through a sucrose cushion, as previously
described (Wiegand et al., 2004). This analysis also allowed us
to address the important question of whether any of the
introduced mutations destabilized A3G or A3B and to confirm
that none of the APOBEC3 proteins tested had any effect on the
production and release of HIV-1 virions (Figs. 1C and D).As shown in Fig. 1D, the A3B-E2 and A3B-C2 mutants were
expressed at intracellular levels that were comparable to wild-
type and were also incorporated into HIV-1 virions with an
efficiency that was similar to the wild-type A3B protein. The E1
and C1 mutations appeared to give rise to a slightly lower level
of intracellular A3B protein expression, for both the single CDA
mutants A3B-E1 and A3B-C1 and both double CDA mutants
(Fig. 1D). These mutations also gave rise to a slightly lower
level of incorporation of A3B into HIV-1 virions (Fig. 1D).
However, when compared to the HA-tagged cytoplasmic
negative control protein β-arrestin, it was clear that all A3B
mutants were still being selectively incorporated into HIV-1
virions at levels that varied by no more than ∼3-fold. Analysis
of the incorporation of the A3G mutants into HIV-1 virions
showed that all A3G mutants were expressed at comparable
levels in the virion producer cells (Fig. 1C). In agreement with
previous reports (Navarro et al., 2005; Hakata and Landau,
2006), the introduction of mutations into the carboxy-terminal
CDA of A3G had no detectable effect on the incorporation of
A3G into HIV-1 virions (Fig. 1C). In contrast, introduction of
either the E1 or the C1 mutation clearly reduced A3G virion
incorporation by ∼4-fold. Moreover, A3G variants carrying
mutations in both CDAs appeared to be essentially lost from
HIV-1 virion particles (Fig. 1C).
Fig. 2. Effect of APOBEC3 protein expression on the level of mutation detected
in bacteria. This analysis measures the ability of APOBEC3 proteins to induce a
mutator phenotype in bacteria, as determined by acquisition of resistance to
the antibiotic rifampicin (Rif R). Plasmids that encode the indicated APOBEC3
proteins were introduced into E. coli strain BW310 and their expression ac-
tivated using isopropyl β-D-thiogalactoside. The level of mutation induced by
each protein was then quantified by plating the bacteria on media containing
rifampicin and counting the number of resistant colonies. The parental pTrc99A
expression plasmid served as the negative control. (A) Analysis of the mutator
phenotype of wild-type human APOBEC3 proteins. Average of three
experiments. The Western blot analyzing the expression of each protein in
bacteria was performed using an HA-tag-specific antibody. APOBEC3 proteins
containing 2 CDAs, i.e., A3B, A3F and A3G, are detected in both their full-
length, ∼42-kDa form and as a breakdown product of ∼22 kDa that likely
represents the HA-tagged carboxy-terminal CDA domain. (B) Analysis of the
mutator phenotype of CDA mutants of A3G or A3B. Data are given as a
percentage of the mutator activity seen with the wild-type A3G or A3B protein,
which was set at 100%. Average of three experiments with standard deviation
indicated. AWestern blot showing the expression level of the full-length, ∼42-
kDa forms of each A3B or A3G variant in bacteria is presented at the bottom of
the figure.
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APOBEC3 proteins in bacteria
As noted above, it has been reported that the carboxy-
terminal CDA is the only enzymatically active CDA for both
A3G and A3B (Haché et al., 2005; Navarro et al., 2005;
Newman et al., 2005; Hakata and Landau, 2006; Stenglein and
Harris, 2006). We wished to confirm this result and also to
measure the cytidine deaminase activity of the various A3G and
A3B mutants. As one approach to this question, we used a
previously described assay (Beale et al., 2004; Bogerd et al.,
2006a; Jónsson et al., 2006) that measures the ability of an
expressed gene product to enhance the level of mutagenesis of
the RNA polymerase B (rpoB) gene in Escherichia coli.
Mutations in rpoB can be readily detected by measuring the
frequency of rifampicin resistant (rif R) colonies.
We first compared the ability of a range of different human
APOBEC3 proteins to induce hypermutation. A3A, A3B and
A3C all increased the number of rifR bacteria by 100- to 150-fold
(Fig. 2A). In contrast, expression of A3G enhanced the number
of rifR colonies by ∼5.4-fold while A3F only had a ∼1.6-fold
enhancing effect over background. Because A3B, A3G and A3F
are all effective at introducing C to T mutations into HIV-1
proviruses produced in their presence (Harris et al., 2003;
Mangeat et al., 2003; Bishop et al., 2004; Liddament et al., 2004;
Wiegand et al., 2004; Doehle et al., 2005), these data imply that
the mutational activity of APOBEC3 proteins observed in the
bacterial mutator assay is not an accurate predictor of their
DNA editing activity in retroviral virions. Indeed, it has
recently been reported that murine APOBEC3, which is
highly active in editing HIV-1 reverse transcripts produced in
its presence, is inactive in the bacterial mutator assay (Jónsson
et al., 2006). Importantly, as shown by Western analysis (Fig.
2A), these differences do not result from differences in the
level of expression of the various APOBEC3 proteins in
bacteria.
With the above caveat in mind, we next asked whether the
very high mutator activity of A3B, or the modest but readily
detectable mutator activity seen with A3G, would in fact be
affected by any of the single CDAmutants. As shown in Fig. 2B,
and consistent with previous reports (Navarro et al., 2005;
Newman et al., 2005; Hakata and Landau, 2006; Jónsson et al.,
2006; Stenglein and Harris, 2006), we found that mutation of the
amino-terminal CDA of A3G or A3B, in the E1 and C1 mutants,
had no significant effect on the bacterial mutator activity of these
proteins. In contrast, both the E2 and the C2 mutation inhibited
the ability of either A3B or A3G to induce hypermutation of
bacterial DNA.
Both CDAs present in A3B are enzymatically active
Because of the clearly non-linear relationship between the
editing activity of human APOBEC3 proteins in HIV-1 reverse
transcription complexes and their ability to induce hypermuta-
tion in bacteria (Fig. 2A), we next directly measured the editing
of HIV-1 reverse transcripts produced in the presence of wild-
type or mutant variants of A3G and A3B.In the case of A3G, the expected result (Navarro et al., 2005;
Newman et al., 2005) was obtained. That is, wild-type A3G
introduced a high level of C to T mutations into HIV-1 reverse
transcripts (Fig. 3A) while both the A3G-E2 and the A3G-C2
mutant failed to induce a level of proviral DNA editing that was
above background (Figs. 3B and C). In the case of wild-type
A3B, we again detected a high level of C to T mutagenesis (Fig.
Fig. 3. Analysis of C to T editing of HIV-1 reverse transcripts by A3G and A3B CDA mutants. To analyze the level of C to T editing by the various CDA mutants, we
generated HIV-1 virions in the presence of each protein and used these to infect naive 293Tcells. At 16 h after infection, total cellular DNAwas harvested, cleaved with
DpnI and then a region of the env gene of HIV-1 amplified using a high fidelity Taq polymerase. After cloning and sequencing, the number of introduced missense
mutations was quantified and is here presented in tabular form for each wild-type or mutant APOBEC3 protein. The original HIV-1 sequence is given at left and the
new sequence across the top. The total number of bases sequenced is shown at the lower right of each box.
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result (Hakata and Landau, 2006; Stenglein and Harris, 2006),
i.e., we detected a level of C to T editing that was well over
background but somewhat lower than observed with wild-type
A3B (Fig. 3E), a difference that could potentially be ascribed to
the slightly lower level of A3B-E1 that is packaged into HIV-1
virions (Fig. 1D). The surprising result was obtained with A3B-
E2, which gave rise to a level of C to T editing of HIV-1 reverse
transcripts that was both well over background and closely
comparable to the level seen in A3B-E1 (Fig. 3F). To confirm
that an A3B mutant lacking a functional carboxy-terminal CDA
active site is indeed still capable of inducing DNA editing, we
alsomeasure editing of HIV-1 reverse transcripts produced in the
presence of A3B-C2 (Fig. 3G). Again, we observed a level of C
to T editing that was clearly above background. To confirm that
the E1 and E2 mutations are indeed able to inactivate the CDA
active sites present in A3B, we also measured editing induced by
A3B-E1+E2. As shown in Fig. 3H, no significant level of C to T
editing was detected. In conclusion, these data confirm earlier
data (Navarro et al., 2005; Newman et al., 2005; Jónsson et al.,
2006) showing that only the carboxy-terminal CDA in A3G is
active and demonstrate that both CDAs in A3B have thepotential to independently induce editing of HIV-1 reverse
transcripts.
Consensus sites for editing by A3B
An interesting aspect of the various human APOBEC3
proteins is that they all have characteristic consensus sites for
editing. As shown in Fig. 4A, and previously reported, A3G
prefers to edit C residues flanked by a 5′ C residue (Harris et al.,
2003; Bishop et al., 2004; Wiegand et al., 2004; Khan et al.,
2005). In contrast, A3B prefers to edit C residues flanked by a 5′
T residue, although a significant number of C residues flanked 5′
by C are also edited (Fig. 4B) (Bishop et al., 2004; Doehle et al.,
2005). We therefore asked whether the amino- and carboxy-
terminal CDA active sites of A3B might have different editing
preferences. As shown in Fig. 4, the A3B-E1 mutant has a strong
preference for TC while the A3B-E2 mutant prefers to edit CC.
Discussion
The goal of this research was to examine the importance of
the two CDAs present in the dual CDA domain APOBEC3
Fig. 4. Consensus editing sequences for A3B CDAmutants. This figure presents
the sequence context of the C to T mutations tabulated for each of the indicated
APOBEC3 proteins. In particular, this figure shows the 5′ and 3′ flanking
nucleotide around each edited C residue.
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infectivity. Previous research on this topic has largely focused on
the ability of A3G, and to a lesser extent A3F, mutants to inhibit
HIV-1 infectivity (Navarro et al., 2005; Newman et al., 2005;
Jónsson et al., 2006; Holmes et al., 2007). Here, we have
extended these earlier data by also examining a less well under-
stood human APOBEC3 protein, A3B.
Mutants of A3G and A3B that are enzymatically inactive retain
antiretroviral activity
An important conclusion to emerge from the research re-
ported in this manuscript is that mutants of A3G or A3B that are
inactive as cytidine deaminases nevertheless retain significant
inhibitory activity against HIV-1. Specifically, the enzymatically
inactive (Fig. 3) A3G-E2 and A3G-C2 mutants remained able
to inhibit HIV-1 infectivity by ∼4-fold (Fig. 1A) while the
A3B-E1+2 and A3B-C1+2 mutants could inhibit HIV-1 in-
fectivity by∼8-fold (Fig. 1B). Nevertheless, these mutant forms
of A3G and A3B were clearly less active than wild type. In part,
at least in the case of A3B-E1+2 and A3B-C1+2, this reduced
activity could reflect the somewhat reduced incorporation of
these mutant proteins into HIV-1 virion particles when compared
to wild-type A3G (Fig. 1D).
Our conclusion that proviral editing is not the only mecha-
nism for inhibition of retroviral infectivity, and may not be the
major mechanism, echoes conclusions reached byNewman et al.
(2005); Bishop et al. (2006); Holmes et al. (2007), although our
results differ from their published data in significant ways.Specifically, Newman et al. (2005) reported that A3G mutants
lacking a functional carboxy-terminal CDA, including mutants
identical to A3G-E2 (E259Q) and A3G-C2 (C288S), retained
almost full antiviral activity when assayed using HIV-1, yet
introduced no C to Tmutations into HIV-1 reverse transcripts. In
contrast, our results (Fig. 1A) and work published by other
groups using these same A3G mutants (Mangeat et al., 2003;
Shindo et al., 2003; Hakata and Landau, 2006; Jónsson et al.,
2006), argue that A3G mutants lacking a functional carboxy-
terminal CDA are actually significantly attenuated for inhibition
of HIV-1 infectivity. Recent data from the Malim laboratory
have revealed that strong inhibition of HIV-1 by A3G-E2
(E259Q) actually is only observed when very high levels of
A3G-E2 are expressed (Holmes et al., 2007). In contrast, the data
presented in Fig. 1Awere obtained using a fairly modest level of
A3G expression that was chosen because it allowed full recovery
of HIV-1 infectivity when a wild-type, i.e., Vif-expressing, HIV-
1 proviral indicator construct was analyzed (Wiegand et al.,
2004).
Despite these minor discrepancies among the published data,
it nevertheless seems clear that A3G variants lacking an intact
carboxy-terminal CDA do retain some ability to inhibit HIV-1
infectivity (Fig. 1A) (Newman et al., 2005; Jónsson et al., 2006;
Holmes et al., 2007). This result has been even more apparent
when mutants of A3F bearing a mutated carboxy-terminal CDA
have been analyzed (Jónsson et al., 2006; Holmes et al., 2007).
The data presented in this manuscript extend this earlier work by
showing that enzymatically inactive forms of A3B also retain
substantial inhibitory activity against HIV-1 (Fig. 1B).
A3B contains two enzymatically active CDAs
An interesting observation reported here is that A3B actually
contains two enzymatically active CDAs, as revealed by the
ability of not only A3B-E1 but also A3B-E2 and A3B-C2 to
induce C to Tmutagenesis of HIV-1 reverse transcripts produced
in their presence (Fig. 3). A3G and A3F have previously been
reported to contain only one enzymatically active CDA, located
near the carboxy-terminus (Navarro et al., 2005; Newman et al.,
2005; Haché et al., 2005; Hakata and Landau, 2006; Jónsson et
al., 2006). Several non-human APOBEC3 proteins bearing two
CDA domains have also been shown to contain only a single
enzymatically active CDA, although in the case of murine
APOBEC3 and bovine and ovine A3F, this appears to be the
amino-terminal CDA (Hakata and Landau, 2006; Jónsson et al.,
2006). In fact, it has previously also been reported that only the
carboxy-terminal CDA of A3B is enzymatically active in
mammalian cells (Hakata and Landau, 2006). We do not know
the basis for this discrepancy, although we note that the single
carboxy-terminal CDAmutant tested in this previous report, i.e.,
glutamic acid 255 to alanine, was not tested in our analysis and
could be more disruptive to the structure of A3B than the more
conservative A3B-E2 mutation (i.e., E255Q).
As A3B clearly contains two enzymatically active CDAs
(Fig. 3), we were curious to determine whether these had
different consensus editing sequence preferences. As shown in
Fig. 4, and as previously reported, A3B edits cytidine residues
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et al., 2004; Doehle et al., 2005). Analysis of the editing
preferences of the A3B-E1 and A3B-E2 mutants indicates that
the carboxy-terminal CDA of A3B strongly prefers to edit TC,
while the amino-terminal CDA prefers to edit CC. These results
suggest that the consensus editing sequence preference of the
wild-type A3B protein may, in fact, be a composite of these two
individual CDA activities.
Although the A3B-E2 and A3B-C2 mutants retained a
significant ability to edit HIV-1 reverse transcripts (Fig. 3), they
were unable to edit the rpoB gene in bacteria even though they
were expressed at levels comparable to wild-type A3B (Fig. 2).
These data recall the recent observation that the wild-type
murine A3 protein, which is a potent editor of HIV-1 reverse
transcripts when expressed in infected cells, is also inactive in
this bacterial mutator assay (Jónsson et al., 2006). Together,
these data clearly demonstrate that the inability to edit the rpoB
gene in bacteria does not reliably indicate an inability to edit
retroviral reverse transcripts in vivo. Why some mammalian
cytidine deaminases are effective at genomic DNA editing when
expressed in bacteria, while others are apparently inactive, cur-
rently remains unclear.
Materials and methods
Molecular clones
We have previously described mammalian expression plas-
mids, derived from pK, that express C-terminally HA-tagged
forms of A3B, A3G and β-arrestin (Bogerd et al., 2006b).
Mutant forms of the pK/A3G-HA and pK/A3B-HA expression
plasmids bearing single or double point mutations were gen-
erated by PCR and confirmed by DNA sequence analysis.
The HIV-1 proviral derivatives pNL-LucΔVif and pNL4-
3ΔVifΔEnv and the VSV glycoprotein expression plasmid
pHIT/G have been previously described (Wiegand et al., 2004).
Wild-type or mutant forms of A3B and A3G were transferred
from pK into the bacterial expression plasmid pTrc99A (AB
Biosciences, Piscataway, NJ) as previously described (Bogerd
et al., 2006b).
Retroviral infectivity assays
Experimental determinations of the effect of APOBEC3
proteins on the infectivity of HIV-1 were performed as
previously described (Wiegand et al., 2004; Doehle et al.,
2005). 293Tcells (35-mm plates) were transfected with 1.5 μg of
pNL-LucΔVif, 125 ng of an APOBEC3 expression plasmid and
875 ng of pK. The pK/β-Arr-HA plasmid served as the negative
control. At 48 h after transfection, supernatant media were
harvested, filtered and used to infect 293T cells expressing CD4
and CXCR4. A further 24 h later, the infected cells were lysed
and induced luciferase levels quantified.
For analysis of HIV-1 proviral DNA editing, 293T cells
(35-mm dishes) were transfected with 1.5 μg of pNL-LucΔVif,
500 ng of an APOBEC3 expression plasmid, 500 ng of pK and
100 ng of pHIT/G. The resultant virions were collected at 48 hpost-transfection and used to infect naive 293T cells. After 4 h,
the infected cells were washed and fresh media added. Infection
was allowed to proceed for a further 12 h, at which point total
DNAwas harvested from the cells. Isolated DNAwas digested
with DpnI (New England Biolabs) to remove any contaminating
plasmid DNA. A region of the proviral env gene containing
DpnI sites was then amplified using Taq Plus precision poly-
merase (Stratagene), cloned and sequenced (Wiegand et al.,
2004).
For analysis of the packaging efficiency of APOBEC3
proteins into virions, 293T cells (10-cm dishes) were transfected
with 9 μg of pNL4-3ΔEnvΔVif together with 750 ng of an
APOBEC3 expression plasmid and 5.25 μg of pK. HIV-1 virions
were collected at 48 h after transfection by ultracentrifugation,
as previously described (Wiegand et al., 2004; Doehle et al.,
2005), and the producer cells lysed for analysis of intracellular
protein expression levels. Western analyses of virion and cel-
lular proteins were then performed using a mouse mono-
clonal specific for the HIV-1 capsid protein (Chesebro et al.,
1992) and a mouse monoclonal specific for the HA epitope tag
(Covance).
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